CORT May 2023 23.000 put
| Previous close | 2.3000 |
| Open | 2.3000 |
| Bid | 1.5500 |
| Ask | 2.1000 |
| Strike | 23.00 |
| Expiry date | 2023-05-19 |
| Day's range | 2.3000 - 2.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
- Investing.com
5 big stock buybacks: Verisk, Con Edison | Pro Recap
Here are 5 biggest share buyback announcements from the past week you may have missed on InvestingPro. Verisk Analytics (NASDAQ:VRSK) announced that it has entered into accelerated share repurchase agreements with each of Citibank, and Goldman Sachs to repurchase an aggregate of $2.5B of the company's common stock. Morgan Stanley said on Thursday it's adding a position to the company, given (1) industry-standard network effects in an attractive industry, (2) attractive valuation after the company’s return to its traditional property and casualty-focused end markets after selling non-core business segments, and (3) from a portfolio perspective, reduces the Model’s volatility and exposure to consumer discretionary while adding exposure to high-quality industrials.
- GlobeNewswire
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock
MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has commenced a modified Dutch Auction tender offer for the purchase of up to 7,500,000 shares of Corcept’s common stock, par value $0.001 per share (
- Simply Wall St.
Corcept Therapeutics Full Year 2022 Earnings: EPS Misses Expectations
Corcept Therapeutics ( NASDAQ:CORT ) Full Year 2022 Results Key Financial Results Revenue: US$401.9m (up 9.8% from FY...
